CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.

ABSTRACT:

Background

Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is unclear. For example, when to initiate highly active antiretroviral therapy (HAART) during HIV-1 infection remains a clinical dilemma. This decision relies heavily on assessing AIDS risk based on the CD4+ T cell count and plasma viral load. However, the trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk.

Methods and findings

In a prospective, single-site, ethnically-mixed

SUBMITTER: Kulkarni H 

PROVIDER: S-EPMC2522281 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature